Shares of Athenex, Inc. (NASDAQ:ATNX) have been assigned a consensus broker rating score of 1.50 (Buy) from the two analysts that cover the company, Zacks Investment Research reports. One investment analyst has rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company.

Analysts have set a 12-month consensus target price of $27.50 for the company, according to Zacks. Zacks has also given Athenex an industry rank of 159 out of 265 based on the ratings given to its competitors.

A number of research analysts recently weighed in on the company. Laidlaw assumed coverage on Athenex in a research note on Tuesday, September 19th. They issued a “buy” rating and a $36.00 price objective on the stock. Credit Suisse Group assumed coverage on Athenex in a research note on Monday, September 18th. They issued an “outperform” rating and a $25.00 price objective on the stock. Royal Bank Of Canada assumed coverage on Athenex in a research note on Thursday, September 14th. They issued an “outperform” rating and a $35.00 price objective on the stock. Finally, Deutsche Bank AG assumed coverage on Athenex in a research note on Monday, July 10th. They issued a “buy” rating and a $20.00 price objective on the stock.

Several hedge funds have recently modified their holdings of ATNX. Bank of New York Mellon Corp bought a new position in shares of Athenex in the 2nd quarter valued at approximately $240,000. Tudor Investment Corp ET AL bought a new position in Athenex in the 2nd quarter worth approximately $320,000. Goldman Sachs Group Inc. bought a new position in Athenex in the 2nd quarter worth approximately $601,000. California Public Employees Retirement System bought a new position in Athenex in the 2nd quarter worth approximately $800,000. Finally, Vanguard Group Inc. bought a new position in Athenex in the 2nd quarter worth approximately $800,000. 0.88% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “Athenex, Inc. (ATNX) Receives Consensus Rating of “Buy” from Analysts” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another site, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this article can be accessed at https://www.thecerbatgem.com/2017/10/11/athenex-inc-atnx-receives-consensus-rating-of-buy-from-analysts.html.

Athenex (ATNX) traded down 0.84% during mid-day trading on Friday, reaching $18.99. 94,483 shares of the company were exchanged. Athenex has a 12 month low of $11.21 and a 12 month high of $20.79. The company’s market cap is $1.08 billion. The stock’s 50-day moving average is $17.43 and its 200-day moving average is $16.77.

Athenex (NASDAQ:ATNX) last issued its quarterly earnings data on Monday, August 14th. The company reported ($0.88) earnings per share for the quarter. The company had revenue of $4.60 million during the quarter. Equities analysts expect that Athenex will post ($2.22) earnings per share for the current year.

About Athenex

Athenex, Inc is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company’s technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics.

Get a free copy of the Zacks research report on Athenex (ATNX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for Athenex Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex Inc. and related stocks with our FREE daily email newsletter.